Admedus (ASX:AHZ) said today that it agreed to sell its vaccines business to Constellation Therapeutics in a deal that will see it own nearly 30% of the Chinese company. Other shareholders in the vaccines would own another 11%, Queensland, Australia-based Admedus said. Sun Bright Holdings will own the remainder and put in $18 million until November […]
Admedus wins CE Mark for CardioCel 3D, VascuCel products
Admedus (ASX:AHZ) has won CE Mark approval in the European Union for its CardioCel 3D and VascuCel products which use its proprietary Adapt tissue technology, according to a report from ProactiveInvestors. The Australian company plans to begin the first stage of a commercial launch of the devices in the region later this month, according to the […]
Medtronic expands paid family leave benefits for US employees | Personnel Moves – May 1, 2018
Medtronic (NYSE:MDT) today announced expanded paid family leave benefits which the company says will “allow for greater employee flexibility while balancing work and family priorities.” The new benefits, which went into effect today, cover full and part-time US employees and allow for a “wide range of family care leave needs,” the Fridley, Minn.-based company said. These […]
How to regenerate a regenerative company: Admedus CEO Paterson on the company’s turnaround efforts
For over a year, Admedus (ASX:AHZ) has been engaged in a significant restructuring effort as it looks to break trends of overspending and edge towards profitability. The company is finally seeing fruits of its labors, posting its 1st cashflow neutral quarter this year and looking to a hopeful turn to profitability in the future. To lead […]
Admedus touts Phase II follow-on data for CardioCel
Admedus (ASX:AHZ) yesterday released results from the Phase II extension study of its CardioCel regenerative used to repair congenital heart defects in pediatric patients, touting no signs of calcification or need for repeat procedures. Admedus’ CardioCel bio-scaffolds are regenerative tissue patches designed for cardiac and vascular repairs and reconstructions and promote autologous growth. “This is a significant […]
Admedus shares rise on hospital infusion pump supply deal with Arcomed
Admedus (ASX:AHZ) said today it won a supply contract with the new Royal Adelaide Hospital for the installation of the Arcomed chroma infusion pump systems. Swiss infusion technology company Arcomed’s Chroma infusion pumps are designed to provide a whole-of-hospital system and include LCD touch screens, drug error reduction systems and on-screen color coding of medication, Admedus said. […]
Fonar taps MR scan inventor and founder’s son as CEO | Personnel Moves
Fonar Corp (NSDQ:FONR) said yesterday it named Timothy Damadian, son of magnetic resonance scanning inventor and company founder Dr. Raymond Damadian, as its new president and CEO. The younger Damadian worked with Fonar for 16 years, eventually becoming veep of operations. He formed Fonar subsidiary Health Management Corporation of America, which manages medial and diagnostic […]
Admedus inks exclusive distro deal with Coroneo
Admedus (ASX:AHZ) said today it inked an exclusive distribution agreement with Coroneo to sell its Extra aortic annuloplasty ring ing and other heart valve surgery instruments in Germany and the U.K. Canada-based Coroneo’s Extra aortic ring is designed to repair aortic valves by supporting dystrophic aortic tissue and a downsized dilated valve annulus to restore proper cusp contact. “This […]
Down-under medtech firm Admedus looks to future in bio-scaffolds
Australian med-tech company Admedus (ASX:AHZ) is looking to become the “gold standard” in cardiac bio-scaffolds and expand their product into other realms to promote rebuilding of tissue over artificial replacements. Admedus COO Julian Chick spoke to MassDevice.com yesterday about the company’s flagship product CardioCel, how its using bio-scaffolds to grow in the cardiac repair market and […]
Admedus releases new CardioCel scaffold in U.S.
Admedus gains U.S. clearance for cardiovascular scaffold
Admedus won 510(k) clearance from the U.S. FDA for its CardioCel cardiovascular scaffold.
Perth, Australia and Minneapolis, Minn.-based Admedus is developing implantable regenerative technologies. CardioCel, the company’s 1st product, is a pure collagen, bio-compatible regenerative tissue scaffold.
MassDevice Network
@MassDevice
LinkedIn
YouTube